Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Safety Study of Inhaled N-IP-00001 to Determine Tolerability and Safety in Healthy Volunteers.

NCT06662019 is registered in ClinicalTrials.gov with NeoTrials Pty Ltd as lead sponsor.

NCT NCT06662019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06662019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Safety Study of Inhaled N-IP-00001 to Determine Tolerability and Safety in Healthy Volunteers.
Lead sponsor
NeoTrials Pty Ltd
Phase
Phase 1
Overall status
Completed
Start date
October 29, 2024
Completion date
January 15, 2025
Enrollment
8 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy